Search

Displaying results 1731 - 1740 of 4860 in total
  1. Drug

    Moxonidine

    go.drugbank.com/drugs/DB09242
    ApprovedInvestigationalWithdrawn

    It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive.

  2. Drug

    Oxybutynin

    go.drugbank.com/drugs/DB01062
    ApprovedInvestigational

    It is often used as first-line therapy for OAB.[A185990]

  3. Drug

    Diltiazem

    go.drugbank.com/drugs/DB00343
    ApprovedInvestigational

    It works through various mechanisms of action, but it primarily works by inhibiting the calcium influx into cardiac and vascular smooth muscle during depolarization. … Approved in 1982 by the FDA, it is a member of the non-dihydropyridine calcium channel blockers drug class.

  4. Drug

    Butalbital

    go.drugbank.com/drugs/DB00241
    ApprovedIllicit

    There have not been clinical trials that evaluate the clinical efficacy of butalbital in migraines [A177754] thus it is not indicated for such condition. … It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervous system (CNS) depression that ranges from mild sedation

  5. Drug

    Sacituzumab govitecan

    go.drugbank.com/drugs/DB12893
    ApprovedInvestigational

    As a targeted cytotoxic agent, it is hoped to provide similar efficacy with reduced adverse effects. … .; it is currently indicated under accelerated approval for the treatment of mTNBC patients who have undergone two or more prior therapies.

  6. Drug

    Dosulepin

    go.drugbank.com/drugs/DB09167
    ApprovedInvestigational

    It is not FDA-approved due to low therpeutic index and significant toxicity in overdose.

  7. Drug

    Olaparib

    go.drugbank.com/drugs/DB09074
    ApprovedInvestigational

    [L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health Canada in April 2016.[L42820]

  8. Drug

    Elivaldogene autotemcel

    go.drugbank.com/drugs/DB16746
    Approved

    It was approved by the European Commission in July 2021 under the market name Skysona, and was later withdrawn in November 2021 at the request of the marketing-authorization holder. … It is used to provide functional copies of human adrenoleukodystrophy protein (ALDP) in patients with adrenoleukodystrophy,[L39491] an X-linked genetic disorder characterized by missing or non-functional

  9. Drug

    Butylscopolamine

    go.drugbank.com/drugs/DB09300
    ApprovedInvestigationalVet approved

    It is not a pain medication in the normal sense, since it does not directly affect pain, but rather works to prevent painful cramps and spasms from occurring. … It is used to treat pain and discomfort caused by abdominal cramps, menstrual cramps, or other spasmodic activity in the digestive system. It is also effective at preventing bladder spasms.

  10. Drug

    Ingenol mebutate

    go.drugbank.com/drugs/DB05013
    ApprovedWithdrawn

    Ingenol mebutate was approved by the FDA in January 2012, and it is marketed under the name Picato®. Picato gel is indicated for the topical treatment of actinic keratosis.